A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy

T-cell immunotherapies, such as CAR-T immunotherapy, are being developed against a wide variety of diseases. Here the authors report the feeder-free, scalable differentiation of human induced pluripotent cells (iPSCs) to T-cells with T-cell receptor dependent anti-tumour function in vitro and in viv...

Full description

Saved in:
Bibliographic Details
Main Authors: Shoichi Iriguchi, Yutaka Yasui, Yohei Kawai, Suguru Arima, Mihoko Kunitomo, Takayuki Sato, Tatsuki Ueda, Atsutaka Minagawa, Yuta Mishima, Nariaki Yanagawa, Yuji Baba, Yasuyuki Miyake, Kazuhide Nakayama, Maiko Takiguchi, Tokuyuki Shinohara, Tetsuya Nakatsura, Masaki Yasukawa, Yoshiaki Kassai, Akira Hayashi, Shin Kaneko
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Science
Q
Online Access:https://doaj.org/article/12a17ede1fbe4df1bb06b871dd8b9d04
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:T-cell immunotherapies, such as CAR-T immunotherapy, are being developed against a wide variety of diseases. Here the authors report the feeder-free, scalable differentiation of human induced pluripotent cells (iPSCs) to T-cells with T-cell receptor dependent anti-tumour function in vitro and in vivo.

Similar Items